AbCellera Biologics Inc. (NASDAQ: ABCL)

AbCellera Biologics Inc. is a clinical stage biotechnology company dedicated to discovering and developing first in class antibody medicines for indications with high unmet medical need. The company has built a proprietary platform that enables the identification and optimization of antibodies against challenging targets such as G protein coupled receptors ion channels multispecific formats and antibody drug conjugates. AbCellera uses this platform to advance its own internal pipeline while also providing antibody discovery and development services to pharmaceutical and biotechnology partners. As of the end of 2025 the company had 2 clinical candidates 2 pre IND candidates and more than 20 active discovery programs across multiple therapeutic areas. Since its inception AbCellera has invested approximately $1 billion in building its antibody discovery and development capabilities which include a 130,000 square foot clinical scale manufacturing facility completed in 2025. As of the end of 2025 the company employed approximately 562 full time staff across its sites in Canada Australia and the United States.

AbCellera generates revenue primarily through its partnership model which includes upfront payments for access research and intellectual property rights, milestone payments tied to preclinical clinical and regulatory achievements, and royalties on the net sales of commercialized medicines derived from its antibodies. The company may also receive out licensing payments and other downstream interests such as equity or co investment rights in its collaborators programs. As of December 31 2025 AbCellera reported approximately $700 million in available liquidity and has received a total of $475.6 million in non dilutive government financing to support platform construction and pipeline development. While the company does not yet have product sales and expects to operate at a loss in the near to medium term it anticipates future revenue from milestone achievements and royalty streams as its partnered and internal programs advance toward commercialization. As of December 31 2025 AbCellera had initiated 104 partner involvement programs that carry the potential for milestone payments and royalty participation. The reported average royalty rate across these programs is 3.3% with a range that has increased over time reflecting the greater value the company contributes to later stage collaborations. The company expects that as these programs progress through clinical development and toward commercialization it will receive milestone payments and royalties that will become a growing source of future revenue.

AbCellera occupies a differentiated niche in the biotechnology industry by focusing on historically difficult targets such as G protein coupled receptors and ion channels where conventional antibody approaches have limited success. Its competitive advantages stem from an integrated discovery engineering and manufacturing platform the application of artificial intelligence to improve screening and design and full control over its supply chain through a newly completed 130,000 square foot clinical scale manufacturing facility. The company faces competition from large pharmaceutical and biotechnology firms that are also pursuing antibody based therapies including Astellas Pharma Bayer Regeneron Sanofi Eli Lilly AbbVie Pfizer Kyowa Kirin Apogee Therapeutics and Bristol Myers Squibb particularly in the areas of vasomotor symptoms and atopic dermatitis. AbCellera seeks to distinguish itself by advancing first in class candidates that may offer improvements in safety dosing frequency and efficacy compared with existing treatments. According to industry data the global therapeutic antibody market reached approximately $300 billion in 2025 and is projected to exceed $500 billion by 2030 representing a compound annual growth rate above 10%. AbCellera’s focus on difficult targets such as G protein coupled receptors and ion channels positions it to capture a share of this expanding market where many competitors have historically struggled. The company also highlights its ability to generate multispecific antibodies and T cell engagers as additional differentiators that broaden its addressable opportunity.

AbCellera’s customer base consists chiefly of pharmaceutical and biotechnology companies that collaborate with the company to leverage its antibody discovery engine. Notable partners include AbbVie Eli Lilly Biogen Viking Global Investors ArrowMark Partners Regeneron Incyte Gilead Sciences Moderna and EQRx among many others. In addition to serving external collaborators AbCellera develops its own pipeline of drug candidates intended to treat patients suffering from conditions such as menopausal vasomotor symptoms atopic dermatitis autoimmune disorders and cancer. Although AbCellera does not currently sell medicines directly to patients its partnered programs are designed to deliver therapies to individuals with high unmet medical needs across multiple therapeutic areas. The company’s strategy is to retain economic interests in the success of these collaborations through royalties milestone payments and other downstream stakes so that its financial performance is linked to the eventual commercialization of the medicines it helps create.